Aurinia Pharmaceuticals Inc.
AUPHNASDAQHealthcare● Active
$15.99
+$0.15(+0.97%)
Market Cap$2.1B
P/E Ratio—
52W High$16.88
52W Low$7.285
Aurinia Pharmaceuticals Inc. (AUPH) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AUPH · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.25
Est. $0.18 · +38.9%
Revenue
$0.08B
Est. $0.08B · +0.9%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
AUPH reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.46
Rev. $3.65B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.46
Rev. Est.$3.65B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 30, 2026 | $0.21 | — | — | — | $0.08B | — |
| ▲ Q2 FY2026 | May 7, 2026 | $0.18 | $0.25 | +38.9% | $0.08B | $0.08B | +0.9% |
| ▲ Q1 FY2026 | Feb 26, 2026 | $0.21 | $0.26 | +23.8% | $0.08B | $0.07B | +3.2% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $0.16 | $0.23 | +43.8% | $0.07B | $0.07B | -1.6% |
| ▼ Q3 FY2025 | Jul 31, 2025 | $0.17 | $0.16 | -5.9% | $0.07B | $0.07B | +3.4% |
| ▲ Q2 FY2025 | May 12, 2025 | $0.08 | $0.16 | +100.0% | $0.06B | $0.06B | -3.4% |
| ▲ Q1 FY2025 | Feb 27, 2025 | $0.03 | $0.09 | +200.0% | $0.06B | $0.06B | -3.2% |
| ▲ Q4 FY2024 | Nov 7, 2024 | $0.01 | $0.10 | +566.7% | $0.07B | $0.07B | +4.2% |
Q3 FY2026
Jul 30, 2026
EPS Actual
—
EPS Est.
$0.21
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
$0.25
EPS Est.
$0.18
EPS Surpr.
+38.9%
Revenue
$0.08B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.26
EPS Est.
$0.21
EPS Surpr.
+23.8%
Revenue
$0.08B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$0.23
EPS Est.
$0.16
EPS Surpr.
+43.8%
Revenue
$0.07B
Q3 FY2025
Jul 31, 2025Miss
EPS Actual
$0.16
EPS Est.
$0.17
EPS Surpr.
-5.9%
Revenue
$0.07B
Q2 FY2025
May 12, 2025Beat
EPS Actual
$0.16
EPS Est.
$0.08
EPS Surpr.
+100.0%
Revenue
$0.06B
Q1 FY2025
Feb 27, 2025Beat
EPS Actual
$0.09
EPS Est.
$0.03
EPS Surpr.
+200.0%
Revenue
$0.06B
Q4 FY2024
Nov 7, 2024Beat
EPS Actual
$0.10
EPS Est.
$0.01
EPS Surpr.
+566.7%
Revenue
$0.07B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.21 | $0.23 | $0.25 | 1 |
| Q3 FY2026 | $0.22 | $0.23 | $0.25 | 2 |
| Q2 FY2026 | $0.21 | $0.23 | $0.24 | 3 |
| Q1 FY2026 | $0.17 | $0.20 | $0.22 | 3 |
| Q4 FY2025 | $0.19 | $0.22 | $0.26 | 4 |
| Q3 FY2025 | $0.15 | $0.16 | $0.17 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.1B | $0.1B | $0.1B | 3 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 4 |
| Q1 FY2026 | $0.1B | $0.1B | $0.1B | 5 |
| Q4 FY2025 | $0.1B | $0.1B | $0.1B | 5 |
| Q3 FY2025 | $0.1B | $0.1B | $0.1B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +38.9% | $16.25 | $15.14 | -6.83% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +23.8% | $14.43 | $13.97 | -3.19% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +43.8% | $13.17 | $14.27 | +8.35% |
| ▼ Q3 FY2025 | Jul 31, 2025 | -5.9% | $9.05 | $9.24 | +2.10% |
| ▲ Q2 FY2025 | May 12, 2025 | +100.0% | $8.00 | $8.12 | +1.50% |
| ▲ Q1 FY2025 | Feb 27, 2025 | +200.0% | $7.95 | $7.55 | -5.03% |
| ▲ Q4 FY2024 | Nov 7, 2024 | +566.7% | $7.52 | $8.34 | +10.90% |
| ▲ Q3 FY2024 | Aug 1, 2024 | +20.1% | $5.88 | $5.61 | -4.59% |
Q2 FY2026-6.83%
Report Date
May 7, 2026
EPS Beat/Miss
+38.9%
Price Before
$16.25
Price After
$15.14
Q1 FY2026-3.19%
Report Date
Feb 26, 2026
EPS Beat/Miss
+23.8%
Price Before
$14.43
Price After
$13.97
Q4 FY2025+8.35%
Report Date
Nov 4, 2025
EPS Beat/Miss
+43.8%
Price Before
$13.17
Price After
$14.27
Q3 FY2025+2.10%
Report Date
Jul 31, 2025
EPS Beat/Miss
-5.9%
Price Before
$9.05
Price After
$9.24
Q2 FY2025+1.50%
Report Date
May 12, 2025
EPS Beat/Miss
+100.0%
Price Before
$8.00
Price After
$8.12
Q1 FY2025-5.03%
Report Date
Feb 27, 2025
EPS Beat/Miss
+200.0%
Price Before
$7.95
Price After
$7.55
Q4 FY2024+10.90%
Report Date
Nov 7, 2024
EPS Beat/Miss
+566.7%
Price Before
$7.52
Price After
$8.34
Q3 FY2024-4.59%
Report Date
Aug 1, 2024
EPS Beat/Miss
+20.1%
Price Before
$5.88
Price After
$5.61
Avg Beat Reaction+0.16%
Avg Miss Reaction+2.10%
Beat Rate7 / 8 quarters
Largest Move+10.90% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AUPH ends December
Aurinia Pharmaceuticals Inc. (AUPH) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.25 — beating the analyst consensus of $0.18 by +38.9%. AUPH has beaten EPS estimates for 3 consecutive quarters. The next AUPH earnings date is expected around September 1, 2026.
Each quarter, investors track AUPH earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AUPH revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AUPH's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AUPH earnings · 5 questionsAurinia Pharmaceuticals Inc.'s next earnings report is expected around September 1, 2026. AUPH typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AUPH historically reports after market close (AMC).
AUPH earnings datewhen is AUPH earningsAUPH next earnings datewhen does AUPH report earningsAUPH earnings calendar
▸ Source: FMP · Aurinia Pharmaceuticals Inc. SEC filings · US GAAP · Aurinia Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026